Todd Kingdom
Concepts (350)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 25 | 2021 | 239 | 3.540 |
Why?
| | Rhinitis | 23 | 2023 | 175 | 3.280 |
Why?
| | Nasal Polyps | 15 | 2017 | 61 | 2.940 |
Why?
| | Endoscopy | 21 | 2024 | 330 | 2.580 |
Why?
| | Paranasal Sinuses | 13 | 2017 | 86 | 1.820 |
Why?
| | Paranasal Sinus Neoplasms | 9 | 2026 | 31 | 1.750 |
Why?
| | Dacryocystorhinostomy | 3 | 2020 | 13 | 1.020 |
Why?
| | Surgery, Computer-Assisted | 3 | 2015 | 84 | 0.960 |
Why?
| | Nasal Mucosa | 6 | 2019 | 111 | 0.930 |
Why?
| | Skull Base | 6 | 2023 | 55 | 0.860 |
Why?
| | Aspirin | 6 | 2016 | 389 | 0.820 |
Why?
| | Cystic Fibrosis | 7 | 2014 | 1124 | 0.720 |
Why?
| | Orbit | 4 | 2016 | 66 | 0.670 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2015 | 342 | 0.560 |
Why?
| | Lipoxygenase | 2 | 2008 | 15 | 0.530 |
Why?
| | Chronic Disease | 19 | 2023 | 1833 | 0.520 |
Why?
| | Postoperative Complications | 7 | 2018 | 2934 | 0.520 |
Why?
| | Sphenoid Sinus | 2 | 2009 | 10 | 0.510 |
Why?
| | Asthma, Aspirin-Induced | 1 | 2015 | 3 | 0.470 |
Why?
| | Decompression, Surgical | 2 | 2017 | 113 | 0.450 |
Why?
| | Graves Ophthalmopathy | 1 | 2015 | 13 | 0.450 |
Why?
| | Paranasal Sinus Diseases | 3 | 2017 | 16 | 0.430 |
Why?
| | Quality of Life | 7 | 2026 | 3165 | 0.410 |
Why?
| | Protein Array Analysis | 2 | 2011 | 58 | 0.370 |
Why?
| | Eosinophilia | 3 | 2016 | 221 | 0.360 |
Why?
| | Bronchiectasis | 1 | 2013 | 112 | 0.360 |
Why?
| | Respiratory System | 1 | 2013 | 160 | 0.360 |
Why?
| | Middle Aged | 35 | 2026 | 35939 | 0.350 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 28 | 0.350 |
Why?
| | Sputum | 1 | 2013 | 314 | 0.340 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 242 | 0.340 |
Why?
| | Rhinitis, Allergic | 4 | 2021 | 44 | 0.340 |
Why?
| | Chemokine CCL5 | 1 | 2011 | 42 | 0.340 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 133 | 0.330 |
Why?
| | Evidence-Based Medicine | 5 | 2016 | 711 | 0.330 |
Why?
| | Tomography, X-Ray Computed | 15 | 2018 | 2798 | 0.320 |
Why?
| | Immunotherapy | 1 | 2015 | 672 | 0.320 |
Why?
| | Humans | 73 | 2026 | 144857 | 0.320 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 26 | 0.320 |
Why?
| | Frontal Sinus | 2 | 2007 | 6 | 0.310 |
Why?
| | Adult | 34 | 2026 | 40438 | 0.310 |
Why?
| | Cerebrospinal Fluid Rhinorrhea | 3 | 2022 | 10 | 0.310 |
Why?
| | Surgical Flaps | 3 | 2019 | 145 | 0.300 |
Why?
| | Leiomyosarcoma | 1 | 2009 | 29 | 0.300 |
Why?
| | Cyclooxygenase 2 | 2 | 2008 | 165 | 0.300 |
Why?
| | Mycoses | 3 | 2005 | 88 | 0.280 |
Why?
| | Odontoma | 1 | 2008 | 4 | 0.280 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2008 | 8 | 0.280 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2008 | 74 | 0.280 |
Why?
| | Aged | 26 | 2026 | 25822 | 0.280 |
Why?
| | Retrospective Studies | 22 | 2022 | 16937 | 0.270 |
Why?
| | Male | 42 | 2026 | 72189 | 0.270 |
Why?
| | Treatment Outcome | 15 | 2024 | 11581 | 0.270 |
Why?
| | Head and Neck Neoplasms | 3 | 2024 | 562 | 0.270 |
Why?
| | Immunoglobulin E | 2 | 2018 | 319 | 0.260 |
Why?
| | Female | 39 | 2026 | 78217 | 0.250 |
Why?
| | Minimal Clinically Important Difference | 1 | 2026 | 30 | 0.240 |
Why?
| | Consensus | 3 | 2021 | 482 | 0.240 |
Why?
| | Nose Neoplasms | 2 | 1996 | 26 | 0.240 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 125 | 0.230 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1531 | 0.230 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 20 | 0.220 |
Why?
| | Osteomyelitis | 1 | 2007 | 142 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 2 | 2016 | 129 | 0.210 |
Why?
| | Hypersensitivity | 3 | 2024 | 266 | 0.210 |
Why?
| | Streptococcus | 1 | 2004 | 29 | 0.210 |
Why?
| | Prednisone | 2 | 2017 | 224 | 0.210 |
Why?
| | Staphylococcus | 1 | 2004 | 74 | 0.210 |
Why?
| | Gram-Negative Bacteria | 1 | 2004 | 79 | 0.210 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 4 | 2011 | 41 | 0.200 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2003 | 16 | 0.200 |
Why?
| | Adenoma | 2 | 2018 | 218 | 0.200 |
Why?
| | Skull Base Neoplasms | 1 | 2023 | 31 | 0.200 |
Why?
| | Bone Diseases | 1 | 2003 | 65 | 0.190 |
Why?
| | Aged, 80 and over | 11 | 2024 | 8185 | 0.180 |
Why?
| | Prospective Studies | 7 | 2026 | 7947 | 0.180 |
Why?
| | Pseudomonas aeruginosa | 4 | 2014 | 350 | 0.170 |
Why?
| | Reoperation | 3 | 2019 | 614 | 0.170 |
Why?
| | Laryngeal Diseases | 2 | 2003 | 32 | 0.170 |
Why?
| | Adolescent | 14 | 2019 | 22396 | 0.170 |
Why?
| | Glucocorticoids | 2 | 2017 | 540 | 0.170 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2020 | 11 | 0.160 |
Why?
| | Nasolacrimal Duct | 1 | 2020 | 12 | 0.160 |
Why?
| | Diagnosis, Differential | 4 | 2018 | 1504 | 0.150 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 5 | 0.150 |
Why?
| | Sella Turcica | 1 | 2018 | 17 | 0.150 |
Why?
| | Nasal Septum | 2 | 2020 | 31 | 0.140 |
Why?
| | Polyethylenes | 1 | 2018 | 17 | 0.140 |
Why?
| | Parotid Diseases | 1 | 1998 | 4 | 0.140 |
Why?
| | Ethmoid Sinus | 2 | 2015 | 9 | 0.140 |
Why?
| | Up-Regulation | 2 | 2012 | 864 | 0.140 |
Why?
| | Sclerosing Solutions | 1 | 1998 | 10 | 0.140 |
Why?
| | Sclerotherapy | 1 | 1998 | 19 | 0.140 |
Why?
| | Otolaryngology | 2 | 2011 | 109 | 0.140 |
Why?
| | Doxycycline | 1 | 1998 | 61 | 0.140 |
Why?
| | Immunohistochemistry | 3 | 2009 | 1734 | 0.140 |
Why?
| | Vision Disorders | 2 | 2017 | 177 | 0.130 |
Why?
| | Immunoglobulin D | 1 | 2017 | 31 | 0.130 |
Why?
| | Mucocele | 1 | 2017 | 13 | 0.130 |
Why?
| | Cysts | 1 | 1998 | 111 | 0.130 |
Why?
| | Prostheses and Implants | 1 | 2018 | 141 | 0.130 |
Why?
| | Melanoma | 2 | 1995 | 813 | 0.130 |
Why?
| | Pituitary Neoplasms | 1 | 2018 | 191 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2015 | 5350 | 0.120 |
Why?
| | Aspergillosis | 1 | 1996 | 23 | 0.120 |
Why?
| | Aspergillus fumigatus | 1 | 1996 | 25 | 0.120 |
Why?
| | Rhinitis, Allergic, Perennial | 2 | 2013 | 23 | 0.120 |
Why?
| | Neuroendoscopy | 1 | 2016 | 24 | 0.120 |
Why?
| | Graves Disease | 1 | 2016 | 30 | 0.120 |
Why?
| | Therapeutic Irrigation | 1 | 2016 | 70 | 0.120 |
Why?
| | Th1-Th2 Balance | 1 | 2015 | 9 | 0.120 |
Why?
| | Visual Acuity | 2 | 2017 | 486 | 0.120 |
Why?
| | Superantigens | 1 | 2015 | 70 | 0.110 |
Why?
| | Forced Expiratory Volume | 2 | 2014 | 493 | 0.110 |
Why?
| | Pharynx | 1 | 1995 | 62 | 0.110 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1996 | 130 | 0.110 |
Why?
| | Nasopharynx | 1 | 2015 | 73 | 0.110 |
Why?
| | Mouth | 1 | 1995 | 91 | 0.110 |
Why?
| | Neck | 3 | 2005 | 110 | 0.110 |
Why?
| | Dinoprostone | 1 | 2015 | 180 | 0.110 |
Why?
| | Meningitis | 1 | 2016 | 80 | 0.110 |
Why?
| | Nasal Cavity | 1 | 1995 | 63 | 0.110 |
Why?
| | Actinomycosis | 1 | 1994 | 5 | 0.110 |
Why?
| | Biocompatible Materials | 1 | 2018 | 436 | 0.110 |
Why?
| | Intraoperative Complications | 1 | 2016 | 155 | 0.110 |
Why?
| | Young Adult | 8 | 2018 | 14033 | 0.110 |
Why?
| | Nose Diseases | 1 | 1994 | 17 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 1 | 1995 | 222 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2016 | 202 | 0.100 |
Why?
| | Cervical Vertebrae | 1 | 1995 | 157 | 0.100 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 392 | 0.100 |
Why?
| | Angiofibroma | 1 | 2013 | 6 | 0.100 |
Why?
| | Pituitary Diseases | 1 | 2013 | 20 | 0.100 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2013 | 20 | 0.100 |
Why?
| | Microbiota | 3 | 2018 | 785 | 0.100 |
Why?
| | HIV Seropositivity | 1 | 1994 | 119 | 0.100 |
Why?
| | Cerebellopontine Angle | 1 | 1993 | 8 | 0.100 |
Why?
| | Biopsy | 3 | 2017 | 1071 | 0.100 |
Why?
| | Case-Control Studies | 5 | 2017 | 3628 | 0.100 |
Why?
| | Granulocytes | 1 | 2013 | 81 | 0.100 |
Why?
| | bcl-X Protein | 1 | 2012 | 45 | 0.090 |
Why?
| | Biofilms | 1 | 2015 | 281 | 0.090 |
Why?
| | Chemoreceptor Cells | 1 | 2013 | 52 | 0.090 |
Why?
| | Transforming Growth Factor beta | 1 | 2015 | 481 | 0.090 |
Why?
| | Microarray Analysis | 1 | 2012 | 118 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 312 | 0.090 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 74 | 0.090 |
Why?
| | Skull Neoplasms | 1 | 2012 | 21 | 0.090 |
Why?
| | Neoplasms, Second Primary | 2 | 2012 | 102 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 290 | 0.090 |
Why?
| | Histocytochemistry | 1 | 2011 | 79 | 0.090 |
Why?
| | Cerebrospinal Fluid Leak | 3 | 2022 | 70 | 0.090 |
Why?
| | Pituitary Gland | 1 | 2012 | 153 | 0.080 |
Why?
| | Cerebellar Neoplasms | 1 | 1993 | 177 | 0.080 |
Why?
| | Incidence | 2 | 2015 | 2865 | 0.080 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2014 | 361 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2013 | 1147 | 0.080 |
Why?
| | Vasoconstrictor Agents | 1 | 2011 | 145 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 423 | 0.080 |
Why?
| | Adaptor Protein Complex beta Subunits | 1 | 2009 | 2 | 0.080 |
Why?
| | Caspase 8 | 1 | 2009 | 47 | 0.070 |
Why?
| | Caspase 9 | 1 | 2009 | 55 | 0.070 |
Why?
| | Epistaxis | 3 | 2011 | 17 | 0.070 |
Why?
| | Bacteria | 1 | 2016 | 894 | 0.070 |
Why?
| | Biopsy, Needle | 1 | 2009 | 184 | 0.070 |
Why?
| | Drug Tolerance | 1 | 2009 | 100 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 75 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 6 | 2013 | 3861 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 858 | 0.070 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2008 | 17 | 0.070 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2008 | 36 | 0.070 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2008 | 20 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1207 | 0.070 |
Why?
| | Maxilla | 1 | 2007 | 36 | 0.070 |
Why?
| | Child | 9 | 2016 | 22620 | 0.070 |
Why?
| | Databases as Topic | 1 | 2007 | 68 | 0.070 |
Why?
| | Fellowships and Scholarships | 1 | 2011 | 355 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2026 | 2971 | 0.060 |
Why?
| | Reference Values | 1 | 2008 | 807 | 0.060 |
Why?
| | Arnold-Chiari Malformation | 2 | 1997 | 29 | 0.060 |
Why?
| | Child, Preschool | 5 | 2011 | 11740 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 553 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 432 | 0.060 |
Why?
| | Linear Models | 1 | 2007 | 860 | 0.050 |
Why?
| | Asthma | 2 | 2016 | 1917 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1913 | 0.050 |
Why?
| | Disease Progression | 1 | 2012 | 2881 | 0.050 |
Why?
| | Risk Assessment | 2 | 2013 | 3580 | 0.050 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6052 | 0.050 |
Why?
| | Pharyngeal Diseases | 1 | 2003 | 17 | 0.050 |
Why?
| | Mouth Diseases | 1 | 2003 | 46 | 0.050 |
Why?
| | Fungi | 1 | 2005 | 161 | 0.050 |
Why?
| | Mutation | 1 | 2014 | 4132 | 0.050 |
Why?
| | HIV Infections | 1 | 1998 | 3082 | 0.050 |
Why?
| | Drug Resistance, Bacterial | 1 | 2004 | 198 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2004 | 373 | 0.050 |
Why?
| | Acute Disease | 2 | 2016 | 1006 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1227 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2004 | 178 | 0.050 |
Why?
| | Antifungal Agents | 1 | 2003 | 151 | 0.050 |
Why?
| | United States | 3 | 2015 | 15723 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 534 | 0.050 |
Why?
| | Head | 1 | 2003 | 120 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 2103 | 0.040 |
Why?
| | Immunocompromised Host | 1 | 2003 | 202 | 0.040 |
Why?
| | Vocal Cord Paralysis | 2 | 1998 | 28 | 0.040 |
Why?
| | Ecchymosis | 1 | 2000 | 3 | 0.040 |
Why?
| | Mitomycin | 1 | 2020 | 33 | 0.040 |
Why?
| | Postoperative Period | 1 | 2022 | 354 | 0.040 |
Why?
| | Genotype | 2 | 2014 | 1841 | 0.040 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2001 | 121 | 0.040 |
Why?
| | Orbital Diseases | 1 | 2000 | 35 | 0.040 |
Why?
| | Elective Surgical Procedures | 1 | 2022 | 198 | 0.040 |
Why?
| | Absorbable Implants | 1 | 2020 | 36 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2004 | 456 | 0.040 |
Why?
| | Drug Implants | 1 | 2020 | 83 | 0.040 |
Why?
| | Meningioma | 1 | 2001 | 87 | 0.040 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 1998 | 4 | 0.040 |
Why?
| | Signal Transduction | 1 | 2012 | 5277 | 0.040 |
Why?
| | Tracheal Neoplasms | 1 | 1998 | 12 | 0.040 |
Why?
| | Laryngeal Neoplasms | 1 | 1998 | 37 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2000 | 249 | 0.030 |
Why?
| | Nasal Decongestants | 1 | 2018 | 8 | 0.030 |
Why?
| | Histamine Antagonists | 1 | 2018 | 19 | 0.030 |
Why?
| | Larynx | 1 | 1998 | 63 | 0.030 |
Why?
| | Skin Tests | 1 | 2018 | 95 | 0.030 |
Why?
| | Epidemiologic Methods | 1 | 2018 | 92 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 186 | 0.030 |
Why?
| | Syndecan-1 | 1 | 2017 | 42 | 0.030 |
Why?
| | Probiotics | 1 | 2018 | 61 | 0.030 |
Why?
| | Plasma Cells | 1 | 2017 | 75 | 0.030 |
Why?
| | Mucus | 1 | 2017 | 79 | 0.030 |
Why?
| | Complementary Therapies | 1 | 2018 | 94 | 0.030 |
Why?
| | Carcinoma | 1 | 1998 | 231 | 0.030 |
Why?
| | Physical Examination | 1 | 2018 | 235 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2940 | 0.030 |
Why?
| | Candidiasis | 1 | 1996 | 64 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 288 | 0.030 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 518 | 0.030 |
Why?
| | Immunoglobulin A | 1 | 2017 | 218 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2017 | 205 | 0.030 |
Why?
| | Chemokines | 1 | 2017 | 224 | 0.030 |
Why?
| | Occupational Diseases | 1 | 2018 | 164 | 0.030 |
Why?
| | Chondrocalcinosis | 1 | 1995 | 1 | 0.030 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 1995 | 2 | 0.030 |
Why?
| | Perioperative Period | 1 | 2016 | 69 | 0.030 |
Why?
| | Odontoid Process | 1 | 1995 | 4 | 0.030 |
Why?
| | Giant Cell Tumors | 1 | 1995 | 4 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1321 | 0.030 |
Why?
| | Atlanto-Axial Joint | 1 | 1995 | 12 | 0.030 |
Why?
| | Surgical Wound Dehiscence | 1 | 1995 | 22 | 0.030 |
Why?
| | Chondrosarcoma | 1 | 1995 | 17 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2016 | 71 | 0.030 |
Why?
| | Chordoma | 1 | 1995 | 17 | 0.030 |
Why?
| | Spinal Neoplasms | 1 | 1995 | 37 | 0.030 |
Why?
| | Water Microbiology | 1 | 2016 | 90 | 0.030 |
Why?
| | Spinal Diseases | 1 | 1995 | 51 | 0.030 |
Why?
| | Hemorrhage | 1 | 2000 | 801 | 0.030 |
Why?
| | Joint Dislocations | 1 | 1995 | 56 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2018 | 326 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1996 | 230 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 192 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1033 | 0.030 |
Why?
| | Joint Diseases | 1 | 1995 | 62 | 0.030 |
Why?
| | Tracheostomy | 1 | 1996 | 142 | 0.030 |
Why?
| | Allergens | 1 | 2018 | 394 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 93 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 501 | 0.030 |
Why?
| | Postoperative Hemorrhage | 1 | 1995 | 97 | 0.030 |
Why?
| | Sweat | 1 | 2014 | 50 | 0.030 |
Why?
| | Biological Products | 1 | 2018 | 252 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2015 | 5809 | 0.030 |
Why?
| | Thyroid Neoplasms | 1 | 1998 | 346 | 0.030 |
Why?
| | Esophageal Neoplasms | 1 | 1998 | 347 | 0.030 |
Why?
| | Nutritional Status | 1 | 1996 | 353 | 0.030 |
Why?
| | Lung Diseases | 1 | 2000 | 796 | 0.030 |
Why?
| | Chlorides | 1 | 2014 | 138 | 0.030 |
Why?
| | Vestibulocochlear Nerve | 1 | 1993 | 7 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2016 | 564 | 0.020 |
Why?
| | Facial Nerve | 1 | 1993 | 39 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1329 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2018 | 588 | 0.020 |
Why?
| | Phospholipase C beta | 1 | 2013 | 30 | 0.020 |
Why?
| | Cranial Nerve Diseases | 1 | 1993 | 43 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2017 | 899 | 0.020 |
Why?
| | Transducin | 1 | 2013 | 42 | 0.020 |
Why?
| | Reproducibility of Results | 2 | 2003 | 3411 | 0.020 |
Why?
| | Perioperative Care | 1 | 2015 | 223 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2013 | 331 | 0.020 |
Why?
| | Angiography | 1 | 2013 | 207 | 0.020 |
Why?
| | Drug Resistance | 1 | 2013 | 154 | 0.020 |
Why?
| | Olfaction Disorders | 1 | 2013 | 70 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 1995 | 317 | 0.020 |
Why?
| | Laryngoscopy | 1 | 2013 | 122 | 0.020 |
Why?
| | Gene Expression | 1 | 2017 | 1517 | 0.020 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 218 | 0.020 |
Why?
| | Surgical Wound Infection | 1 | 2015 | 330 | 0.020 |
Why?
| | Epithelium | 1 | 2013 | 316 | 0.020 |
Why?
| | Risk Factors | 2 | 2018 | 10672 | 0.020 |
Why?
| | Respiratory Tract Diseases | 1 | 2013 | 181 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 772 | 0.020 |
Why?
| | Hematoma | 1 | 2011 | 61 | 0.020 |
Why?
| | Phenylephrine | 1 | 2011 | 75 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2011 | 113 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 638 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 325 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2013 | 233 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 153 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 542 | 0.020 |
Why?
| | Survival Rate | 1 | 1995 | 2051 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 1993 | 1267 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1362 | 0.020 |
Why?
| | Animals | 1 | 2012 | 38331 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 2100 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1058 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 463 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1829 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1193 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1471 | 0.020 |
Why?
| | Societies, Medical | 1 | 2013 | 865 | 0.020 |
Why?
| | Workload | 1 | 2011 | 170 | 0.020 |
Why?
| | Career Choice | 1 | 2011 | 237 | 0.020 |
Why?
| | Down Syndrome | 1 | 1995 | 535 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 2098 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 375 | 0.020 |
Why?
| | Pain | 1 | 2013 | 779 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1995 | 1171 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4279 | 0.010 |
Why?
| | Frontal Sinusitis | 1 | 2005 | 3 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 1993 | 863 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1054 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1332 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 977 | 0.010 |
Why?
| | Lung | 1 | 1996 | 4190 | 0.010 |
Why?
| | Postoperative Care | 1 | 2005 | 283 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5898 | 0.010 |
Why?
| | Clinical Competence | 1 | 2011 | 1238 | 0.010 |
Why?
| | Facial Pain | 1 | 2001 | 13 | 0.010 |
Why?
| | Exophthalmos | 1 | 2001 | 17 | 0.010 |
Why?
| | Adipose Tissue | 1 | 2005 | 657 | 0.010 |
Why?
| | Nasal Obstruction | 1 | 2001 | 28 | 0.010 |
Why?
| | Masks | 1 | 2001 | 70 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 160 | 0.010 |
Why?
| | Headache | 1 | 2001 | 153 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2001 | 127 | 0.010 |
Why?
| | Laryngectomy | 1 | 1998 | 17 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1987 | 0.010 |
Why?
| | Infant | 1 | 2011 | 9987 | 0.010 |
Why?
| | Radiosurgery | 1 | 2001 | 398 | 0.010 |
Why?
| | Algorithms | 1 | 1998 | 1848 | 0.010 |
Why?
|
|
Kingdom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|